JAK2 and acute myeloid leukemia: The incidence of mutated NOTCH1 (13/186, 7.0%), JAK2 (16/186, 8.6%), and TET2 (17/186, 9.1%), which were scarcely reported for their clinical implications in t(8;21) AML, was detected to be relatively lower but not rare in our cohort.